

# Guillaume P Andrieu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7319080/publications.pdf>

Version: 2024-02-01

9  
papers

179  
citations

1307543

7  
h-index

1588975

8  
g-index

9  
all docs

9  
docs citations

9  
times ranked

398  
citing authors

| # | ARTICLE  | IF   | CITATIONS |
|---|--|------|-----------|
| 1 | BET Proteins Exhibit Transcriptional and Functional Opposition in the Epithelial-to-Mesenchymal Transition. <i>Molecular Cancer Research</i> , 2018, 16, 580-586.          | 3.4  | 46        |
| 2 | BET protein targeting suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer and elicits anti-tumor immune response. <i>Cancer Letters</i> , 2019, 465, 45-58. | 7.2  | 36        |
| 3 | BET proteins in abnormal metabolism, inflammation, and the breast cancer microenvironment. <i>Journal of Leukocyte Biology</i> , 2018, 104, 265-274.                       | 3.3  | 29        |
| 4 | PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL. <i>Blood</i> , 2021, 138, 1855-1869.  | 1.4  | 23        |
| 5 | Blueprint of human thymopoiesis reveals molecular mechanisms of stage-specific TCR enhancer activation. <i>Journal of Experimental Medicine</i> , 2020, 217, .             | 8.5  | 15        |
| 6 | Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup. <i>Science Translational Medicine</i> , 2021, 13, .   | 12.4 | 13        |
| 7 | Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL. <i>Journal of Hematology and Oncology</i> , 2021, 14, 74.                                   | 17.0 | 10        |
| 8 | Adenylate kinase 2 expression and addiction in T-ALL. <i>Blood Advances</i> , 2021, 5, 700-710.  | 5.2  | 7         |
| 9 | Integrated omics approaches to predict T-LBL relapse risk. <i>Blood</i> , 2021, 137, 2280-2282.  | 1.4  | 0         |